MRSN Quote, Financials, Valuation and Earnings

Precision BioSciences has a net margin of -875.93% compared to Mersana Therapeutics's net margin of -70913.79%. Mersana Therapeutics's return on equity of -533.43% beat Precision BioSciences's return on equity of -38.91%.

Mersana Therapeutics has a consensus price target of $4.29, signalling upside risk potential of 1146.21%. On the other hand Precision BioSciences has an analysts' consensus of $30.50 which suggests that it could grow by 557.33%. Given that Mersana Therapeutics has higher upside potential than Precision BioSciences, analysts believe Mersana Therapeutics is more attractive than Precision BioSciences.

Mersana Therapeutics has a beta of 0.787, which suggesting that the stock is 21.338% less volatile than S&P 500. In comparison Precision BioSciences has a beta of 1.428, suggesting its more volatile than the S&P 500 by 42.833%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Precision BioSciences pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $2.8M, which are larger than Precision BioSciences quarterly revenues of $29K. Mersana Therapeutics's net income of -$24.1M is lower than Precision BioSciences's net income of -$20.6M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Precision BioSciences's PE ratio is 3.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.25x versus 0.72x for Precision BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Lifeward has a net margin of -875.93% compared to Mersana Therapeutics's net margin of -96.03%. Mersana Therapeutics's return on equity of -533.43% beat Lifeward's return on equity of -92.59%.

Mersana Therapeutics has a consensus price target of $4.29, signalling upside risk potential of 1146.21%. On the other hand Lifeward has an analysts' consensus of $8.67 which suggests that it could grow by 1089.5%. Given that Mersana Therapeutics has higher upside potential than Lifeward, analysts believe Mersana Therapeutics is more attractive than Lifeward.

Mersana Therapeutics has a beta of 0.787, which suggesting that the stock is 21.338% less volatile than S&P 500. In comparison Lifeward has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.425%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $2.8M, which are smaller than Lifeward quarterly revenues of $5M. Mersana Therapeutics's net income of -$24.1M is lower than Lifeward's net income of -$4.8M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.25x versus 0.26x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -875.93% compared to Mersana Therapeutics's net margin of 21.68%. Mersana Therapeutics's return on equity of -533.43% beat Eli Lilly and's return on equity of 78.25%.

Mersana Therapeutics has a consensus price target of $4.29, signalling upside risk potential of 1146.21%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.08%. Given that Mersana Therapeutics has higher upside potential than Eli Lilly and, analysts believe Mersana Therapeutics is more attractive than Eli Lilly and.

Mersana Therapeutics has a beta of 0.787, which suggesting that the stock is 21.338% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Mersana Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mersana Therapeutics quarterly revenues are $2.8M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Mersana Therapeutics's net income of -$24.1M is lower than Eli Lilly and's net income of $2.8B. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.25x versus 14.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed has a net margin of -875.93% compared to Mersana Therapeutics's net margin of -1105.92%. Mersana Therapeutics's return on equity of -533.43% beat PAVmed's return on equity of --.

Mersana Therapeutics has a consensus price target of $4.29, signalling upside risk potential of 1146.21%. On the other hand PAVmed has an analysts' consensus of $11.50 which suggests that it could grow by 1825.33%. Given that PAVmed has higher upside potential than Mersana Therapeutics, analysts believe PAVmed is more attractive than Mersana Therapeutics.

Mersana Therapeutics has a beta of 0.787, which suggesting that the stock is 21.338% less volatile than S&P 500. In comparison PAVmed has a beta of 1.060, suggesting its more volatile than the S&P 500 by 5.988%.

Mersana Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics pays -- of its earnings as a dividend. PAVmed pays out -- of its earnings as a dividend.

Mersana Therapeutics quarterly revenues are $2.8M, which are larger than PAVmed quarterly revenues of $8K. Mersana Therapeutics's net income of -$24.1M is lower than PAVmed's net income of $19M. Notably, Mersana Therapeutics's price-to-earnings ratio is -- while PAVmed's PE ratio is 0.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics is 1.25x versus 8.79x for PAVmed. Usually stocks with elevated PS ratios are considered overvalued.